Research Progress in the Efficacy and Safety of ALK Inhibitors 
in the Treatment of NSCLC Brain Metastasis

Research Progress in the Efficacy and Safety of ALK Inhibitors 
in the Treatment of NSCLC Brain Metastasis

Lung cancer is one of the most lethal malignancies in the world, with non-small cell lung cancer (NSCLC) accounting for approximately 80%-85% of all pathological types. Approximately 30%-55% of NSCLC patients develop brain metastases. It has been reported that 5%-6% of patients with brain metastases...

Full description

Bibliographic Details
Main Authors: Yuchen CHEN, Han HAN, Jinpan WEI, Qianyu DU, Xiyong WANG
Format: Article
Language:zho
Published: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2023-05-01
Series:Chinese Journal of Lung Cancer
Subjects:
lung neoplasms
alk inhibitors
brain metastasis
efficacy
safety
Online Access:http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.10

Internet

http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.10

Similar Items